Scientists Protected Glaucoma Nerve Cells Without Lowering Eye Pressure — Could Mitochondria Become the Next Treatment Target?

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/scientists-found-a-new-way-to-open-the-eye-s-natural-drainage-system-could-it-lead-to-better-glaucoma-dropsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Scientists Found a New Way to Open the Eye’s Natural Drainage System — Could It Lead to Better Glaucoma Drops? A study published on November 5, 2026 points to a possible new way to improve the eye’s natural fluid drainage: change the mechanical behavior of the cells lining Schlemm’s canal, a circular drainage channel near the front of the eye. In laboratory experiments, the cancer drug paclitaxel altered these cells’ stiffness and pore formation. In isolated mouse eyes, it increased measured fluid outflow facility by 44.3%. That is an intriguing result—but it is not evidence that paclitaxel is a glaucoma treatment, and the experiment did not show a 44.3% fall in eye pressure. The study used cultured human cells and short-term experiments in enucleated mouse eyes, not people receiving eye drops. It also leaves open questions about which drainage tissues produced the effect, whether the proposed signaling pathway explains it, and whether a safer drug can reproduce it. The most careful answer to the central question is: possibly. Restoring a healthier mechanical response in the drainage pathway could become a useful treatment strategy, but the drug, delivery method, and clinical benefit are not yet established. The November 2026 study and its PubMed record () How the eye’s natural drainage system works The eye continually makes a clear fluid called aqueous humor. It flows from behind the iris, through the pupil, and into the front chamber of the eye. Most then leaves through the conventional outflow pathway: It passes through the trabecular meshwork, a porous tissue at the eye’s drainage angle. It crosses a thin layer of cells lining the inner wall of Schlemm’s canal. It enters the canal, then passes into collector channels and veins before joining the circulation. A smaller, separate amount leaves through the uveoscleral pathway, through tissues near the ciliary muscle. The conventional pathway is pressure-dependent: generally, fluid leaves faster when the pressure inside the eye is higher than the pressure in the veins receiving it. The conventional route and aqueous humor circulation are summarized by the National Center for Biotechnology Information () How fluid crosses Schlemm’s canal’s inner wall The inner wall is not simply a passive sieve. Its endothelial cells respond to pressure and stretch. As aqueous humor pushes against them, the cells can bulge toward the canal, forming temporary, fluid-filled outpouchings called giant vacuoles. A pore can form through a stretched cell, allowing fluid to pass into the canal; this is a transcellular pore. Fluid can also pass between neighboring cells through paracellular, or border, pores. A review of Schlemm’s canal cell physiology and a recent review of canal development and function describe both routes. () Pore formation is relevant to glaucoma, but it is not a settled, simple measurement of drainage. Studies of human donor eyes have reported fewer pores in glaucoma, while also showing that postmortem time and tissue fixation affect the apparent pore count. Some researchers have cautioned that at least some observed pores could be artifacts of tissue preparation. A human-eye study reported lower pore density in glaucoma; another study documented the influence of fixation conditions. () What the November 2026 study tested The researchers combined three types of experiment: Cultured primary human Schlemm’s canal cells from donors without glaucoma and donors with glaucoma. Cell mechanobiology tests, including measurements of cell stiffness, contractility-related markers, and mechanically induced pore formation. Whole-eye perfusion experiments in isolated mouse eyes, measuring how readily fluid flowed through the conventional outflow pathway. The study used four normal and four glaucoma-derived human cell strains. Each experiment used a smaller subset, usually three strains per group or condition. The glaucoma-derived strains came from donors aged 71 to 78 years; the normal strains ranged from infancy to 68 years. That age difference is important: donor age may influence cell biology, and the groups were not age-matched. The study’s authors note the limitation. The final published article’s donor table and methods list the strains and experimental details. () Drug concentrations and experimental conditions For the full table, please open this article on visualfieldtest.com. The cultured-cell concentration was 10 micromolar; the nominal concentration in the mouse-eye perfusate was 100 micromolar. Only one principal paclitaxel concentration was tested in each setting, so the study does not establish the lowest effective dose, a dose-response curve, or a safe long-term exposure. The paper’s perfusion methods explain the 100-micromolar perfusate and estimated dilution. () What changed in the cultured cells The reported results included: Lower microtubule-stability markers in glaucoma-derived Schlemm’s canal cells. The researchers measured acetylated alpha-tubulin, a marker associated with stable microtubules. Lower cell stiffness after paclitaxel. In normal cells, paclitaxel reduced measured stiffness by 36.4%; nocodazole increased it by 44.0%. Lower phosphorylated myosin light chain after paclitaxel. After 30 minutes, this contractility-related marker fell by 35.1% (p < 0.01). Filamentous actin did not significantly fall during that short exposure. After 24 hours, the study reported a 58.1% decrease in filamentous actin stress fibers and an 82.9% decrease in phosphorylated myosin light chain. More mechanically induced pores in normal cells. The reported pore incidence rose from 9.0% with vehicle to 11.5% with paclitaxel, an absolute increase of 2.5 percentage points. Nocodazole reduced it to 4.9%. More pore formation after paclitaxel in glaucoma-derived cells. The increase was statistically significant in the strains tested, but the glaucoma-cell pore assay used only three strains and between three and six wells per group. The pore result is often easy to overstate. It was a cell-assay pore incidence, not a measurement that the living eye’s pore count rose by 27.8%, and not a direct measure of a patient’s drainage or eye pressure. The study’s results and figure descriptions report the cell findings and assay conditions. () What changed in the mouse eyes In the eight paired mouse eyes, paclitaxel-treated eyes had 44.3% greater measured outflow facility than their vehicle-treated fellow eyes. Outflow facility is a measure of how readily fluid flows through the pressure-dependent drainage pathway; it is not the same thing as eye pressure. The result is statistically significant according to the authors. Their figure presents confidence intervals for individual eye-facility measurements and a distribution of paired relative differences. However, the article text and figure caption do not give a numerical confidence interval for the 44.3% relative treatment effect. The study involved only eight pairs of eyes, all from healthy mice, and did not test whether paclitaxel lowers pressure in a living mouse with glaucoma. The study’s Figure 6 and methods describe the paired design and statistical tests. () Which links in the proposed chain are established? The study proposes this sequence: > Glaucoma-related tissue stiffening → reduced microtubule stability → increased GEF-H1/RhoA/ROCK signaling → greater cellular contraction → fewer drainage pores → increased outflow resistance → elevated eye pressure The evidence supports some links directly, some only partly, and others mainly as a plausible model. For the full table, please open this article on visualfieldtest.com. The human-eye stiffness results are consistent with earlier work on the Schlemm’s canal inner wall, while the hydrogel experiment directly tested cell response to two substrate stiffnesses. A human donor-eye study of inner-wall stiffness and the 2026 study’s stiffness experiment support these distinctions. () An important complication: paclitaxel may not simply “hold” GEF-H1 on microtubules The 2026 glaucoma study’s explanation treats microtubule stabilization as a way to suppress GEF-H1-linked contraction. But a separate study published in September 2026 found that taxanes—including paclitaxel—can rapidly change the microtubule lattice and release GEF-H1, activating RhoA signaling in other cell systems. That work used cell biology and purified-protein experiments; it did not test human Schlemm’s canal cells. The Nature Cell Biology study reports this taxane-specific effect. () This does not automatically invalidate the glaucoma result. Different cell types, exposure conditions, and microtubule structures may produce different responses. But it does mean that “more stable microtubules” cannot yet be treated as a universal synonym for “less GEF-H1 activity.” The eye study did not directly show that paclitaxel kept GEF-H1 bound to microtubules or lowered RhoA activity in Schlemm’s canal cells. That question needs to be tested directly before the proposed pathway can be considered settled. Acetylation is a marker, not a complete explanation The study used acetylated alpha-tubulin as a marker associated with stable microtubules. The enzyme alSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/hot-tubs-and-glaucoma-the-overlooked-effects-of-warm-water-immersionTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Hot Tubs and Glaucoma: The Overlooked Effects of Warm-Water Immersion A hot tub can affect more than comfort. Warm water and immersion can change blood pressure, heart rate, and blood flow—and these changes may matter to the eye as well as to balance and safety. Yet the limited research does not show that ordinary hot-tub use raises eye pressure or worsens glaucoma. The practical takeaway: For most people whose glaucoma is stable and who have no recent eye-surgery restrictions, a brief, comfortable hot-tub soak is generally reasonable. Glaucoma alone is not a reason to avoid hot tubs. The bigger known concern is dizziness or fainting when getting out. Extra caution makes sense for people with low blood pressure, a history of fainting, concerns about optic-nerve blood flow, or recent glaucoma surgery. How hot water could affect the eye Eye pressure and blood supply are different concerns Glaucoma damages the optic nerve, which carries visual information from the eye to the brain. Intraocular pressure is the pressure of fluid inside the eye. Lowering it is a main way to reduce the risk of further damage. The optic nerve also needs a steady blood supply. Ocular perfusion pressure is an estimate based on blood pressure and eye pressure; it is not a direct measurement of blood flowing through the optic nerve. The American Academy of Ophthalmology notes that low ocular perfusion pressure may contribute to optic-nerve damage, but research cannot always separate the effects of blood pressure from those of eye pressure. Long-term studies have linked low blood-pressure patterns with progression in some people with glaucoma, but they do not show that a normal, brief soak damages the optic nerve. American Academy of Ophthalmology’s glaucoma guidance. () Heat, immersion, and posture can act together Heat widens blood vessels near the skin and can lower blood pressure. Immersion also changes how blood is distributed in the body. Heart rate may rise as the body responds to heat. The combined effect varies from person to person and depends on water temperature, soak length, posture, and health. Posture matters because eye pressure often rises when a person moves from sitting upright to lying flat or with the head lowered. A recent review estimated an average rise of about 2.9 millimeters of mercury when people in the glaucoma spectrum moved from sitting to lying flat. That finding is about body position, not hot tubs. It does not mean that sitting upright in a tub causes the same change. Systematic review of posture-related eye-pressure changes and study of different postures in people with open-angle glaucoma. () What the research says Direct evidence from hot tubs is limited One small study is especially relevant: 34 young, healthy adults sat upright with water up to their shoulders in a 39°C (102°F) hot pool for 20 minutes. Researchers measured eye pressure and blood pressure before the soak, just after it, and five minutes later. Eye pressure and blood pressure fell after immersion, while heart rate increased. The researchers also calculated a decrease in ocular perfusion pressure. This result does not show that a hot tub harms people with glaucoma—or that it treats glaucoma. The participants did not have glaucoma, the study examined only one session, and the measurements were not taken continuously during the soak. The calculated perfusion pressure was an estimate, not a direct measurement of blood reaching the optic nerve. Study of blood and eye pressure after hot-water immersion. () Other warm-water and heat studies are not hot-tub studies Some research helps explain why eye responses may vary, but it should not be treated as proof about hot tubs: In one study, 23 healthy volunteers soaked their feet in 40°C water for one minute. Immediately afterward, their estimated ocular perfusion pressure and a measure of blood-flow speed in the choroid—a blood-vessel layer at the back of the eye—fell briefly. The blood-flow measure was back near its starting level after ten minutes. This was a foot soak, not whole-body immersion, and it did not measure blood flow at the optic nerve. Study of warm foot immersion and choroidal blood flow. () In a different experiment, 12 healthy young men wore a heated suit while resting. This was not a bath or hot tub. After prolonged heat exposure, blood-flow measures in retinal and choroidal vessels decreased, even though blood pressure did not change. The long, controlled exposure is quite different from a typical soak. Study of passive heat stress and ocular blood flow. () A temperature challenge involving people with primary open-angle glaucoma used warm water on one hand, followed by cold water. It was not whole-body bathing. The study therefore cannot establish whether hot tubs are helpful or harmful for people with glaucoma. Study of temperature provocation in glaucoma. () Together, these studies suggest that warmth and immersion can briefly affect blood pressure and some blood-flow measures. They do not establish that hot-tub use causes glaucoma progression. What posture may mean in a tub Most hot-tub use is seated, with the head above water. That is different from lying flat, leaning far back, or keeping the head below the level of the chest for a long time. Posture studies—not hot-tub studies—show that lying flat, lying on one side, or lowering the head can raise eye pressure compared with sitting upright. If you have been told that your eye pressure rises substantially with posture, it is reasonable to ask your eye doctor whether your usual reclining position matters. There is no evidence that people with stable glaucoma need to avoid an ordinary upright soak. () Dizziness, blood pressure, and dehydration Getting out may be riskier than sitting in Heat can lower blood pressure while widening blood vessels. When a person stands, blood can pool in the legs; the body may not adjust quickly enough to keep blood flowing to the brain. This can cause orthostatic hypotension—a blood-pressure drop on standing—with lightheadedness, blurred vision, weakness, or fainting. In one small study, a ten-minute soak in 40°C water caused substantial blood-pressure drops in both people with treated high blood pressure and people with normal blood pressure, although none of the participants reported symptoms. Another study found that a short warm bath temporarily reduced the body’s heart-rate response to standing. These studies are not proof that everyone will feel dizzy, but they show why it is sensible to get out slowly. Hot-tub blood-pressure study and warm-water immersion study of the body’s response to standing. () Long, hot soaks can add fluid loss Being surrounded by water does not prevent sweating. In a study involving 60 minutes of hot-water immersion, participants lost an average of about one liter of fluid, but they also drank a similar amount. That was a prolonged research session, not a typical short soak; it does not mean that every hot-tub visit causes substantial dehydration. Still, starting well hydrated and avoiding a long soak when ill or already dehydrated are sensible precautions. If you have a medical fluid restriction, follow your clinician’s advice rather than increasing fluids on your own. Study of fluid loss during prolonged hot-water immersion. () When the risk assessment may change Talk with your eye doctor or another health professional before using a hot tub—or take extra care—if you have: Advanced or actively worsening glaucoma, especially if your clinician has raised concerns about low blood pressure or blood flow to the optic nerve. Low blood pressure, dizziness on standing, or a history of fainting. A condition that affects the body’s automatic blood-pressure control, such as some nerve disorders. A recent illness, vomiting, diarrhea, or dehydration. Medicines that lower blood pressure or increase fluid loss. Do not stop or change prescribed medicines on your own. Recent glaucoma surgery. Water-exposure instructions vary by procedure and surgeon. Follow your surgical team’s advice before using a hot tub; after some glaucoma operations, water exposure can pose an infection risk. American Academy of Ophthalmology guidance on returning to activity after eye surgery. () Practical precautions for people with glaucoma Keep the water at or below 104°F (40°C), the maximum temperature recommended by the Centers for Disease Control and Prevention. Avoid prolonged soaks, particularly at the hottest setting. Centers for Disease Control and Prevention hot-tub safety guidance. () Prefer a comfortable seated position over lying flat or keeping your head lowered for a long time. Get out slowly. If you are prone to dizziness, use a handhold and have someone nearby. Avoid alcohol before or during a soak. Do not use the tub if you already feel faint, unwell, or dehydrated. Leave the water if you feel lightheaded, nauseated, weak, or unusually unsteady. Do not try to “push through” symptoms. Conclusion For a person with stable glaucoma and no recent surgical restrictions, brief, ordinary hot-tub use is generally reasonable. Current evidence does not show that it raises eye pressure or worsens glaucoma. However, research in people with glaucoma is limited, and warm-water immersion can temporaSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/scientists-found-a-new-way-to-make-injured-optic-nerve-cells-regrow-could-it-help-restore-vision-in-glaucomaTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Scientists Found a New Way to Make Injured Optic Nerve Cells Regrow — Could It Help Restore Vision in Glaucoma? Short answer: The study offers a stronger explanation for how melanopsin can encourage injured retinal ganglion cells to grow axons: light-sensitive signaling through TRPC channels and cyclic adenosine monophosphate appears to work together. The results make the pathway more interesting as a research target, but they do not show that light exposure regrows a human optic nerve, that the new fibers reconnect correctly in the brain, or that vision returns in glaucoma. A reporting caveat matters here. The Proceedings of the National Academy of Sciences paper appeared online on October 27, 2026, and in the November 3, 2026 issue. Its accessible abstract describes the main findings but does not include the detailed axon counts, growth distances, sample sizes, exact statistical tests, or treatment schedule. I cannot verify those numbers from the available full-text record, so I will not invent them. Where possible, I distinguish the new paper from a related 2016 melanopsin study that does report additional experimental details. () What the November 2026 study tested The study used mice with an optic-nerve-crush injury, a laboratory model in which retinal ganglion cell axons are deliberately crushed. The researchers introduced OPN4, the gene for the light-sensitive protein melanopsin, into retinal ganglion cells. They then examined light responses in the cells and assessed axon growth after injury. The paper identifies the successfully infected cells as OPN4-expressing retinal ganglion cells. () The authors compared two broad groups of retinal ganglion cells: Alpha retinal ganglion cells: relatively large cells that include several distinct subtypes. Non-alpha retinal ganglion cells: the diverse remaining population—not one uniform cell type. They report that OPN4-expressing alpha cells produced both a fast, TRPC-dependent light response and a slower, cyclic adenosine monophosphate-dependent response. OPN4-expressing non-alpha cells showed mostly the fast response. The researchers then disrupted the relevant pathways genetically and tested whether supplying cell-permeant cyclic adenosine monophosphate could restore or increase regeneration. () This is more than a simple comparison of “gene therapy versus no gene therapy.” Removing the signaling components and then rescuing one of the effects with cyclic adenosine monophosphate provides evidence that the pathways matter to the reported growth response. It does not, by itself, establish that the resulting axons reconnect to the right brain circuits or restore vision. What the reported numbers do—and do not—show The paper’s accessible abstract reports the direction of the main effects, but not the underlying numerical data. In particular, it does not provide exact axon counts, farthest-growth distances, survival percentages, sample sizes, or p-values. Those numbers should be checked against the article’s figures and supporting information before being quoted. For the full table, please open this article on visualfieldtest.com. “Not stated in the abstract” is not the same as “the result was zero.” It means I cannot responsibly supply a numerical answer without verifying the full paper. The central mechanistic conclusion—that disrupting either pathway reduced the reported regeneration, while cyclic adenosine monophosphate could compensate for part of the deficit—is supported by the published abstract. () What the earlier melanopsin experiment established A related 2016 study provides useful context, but its numbers should not be mistaken for results from the November 2026 paper. In that earlier mouse experiment, researchers delivered melanopsin using an adeno-associated virus, waited four weeks, crushed the optic nerve, and assessed growth two weeks after injury. Some axons extended more than 2 millimeters beyond the injury site. The study’s figure legend reports six mice per group for its main regeneration comparison. () The earlier study also found that retinal ganglion cell survival was similar with and without melanopsin treatment. Among the cells identified as regenerating, 95% were labeled as alpha retinal ganglion cells in one tracing experiment, and 92% in an ex vivo experiment. These findings point to a major limitation: melanopsin expression did not make all retinal ganglion cell types equally regenerative. () That 2016 study did not show that melanopsin-treated axons reached the brain’s superior colliculus. Its researchers checked that the crush had blocked tracing to the superior colliculus, and reported no labeled axons there. The reported growth beyond 2 millimeters was therefore evidence of axon extension, not restored visual circuitry. () How melanopsin could promote growth Melanopsin is a light sensor in some retinal ganglion cells Melanopsin, encoded by OPN4, is normally found in a small subset of retinal ganglion cells called intrinsically photosensitive retinal ganglion cells. Unlike most retinal ganglion cells, these cells can respond directly to light, even without receiving the usual light signals from rod and cone photoreceptors. They contribute especially to non-image-forming functions such as pupil responses and daily body rhythms. () The new study’s approach was to add melanopsin to other retinal ganglion cells. In effect, it gave those cells a new light-sensitive signaling input. The abstract reports that the infected cells developed both rhabdomeric-like and ciliary-like signaling responses—the two pathway motifs the authors associate with melanopsin responses in retinal ganglion cells. () The fast branch: TRPC channels and mTOR In the fast pathway, light activates melanopsin and sets off signaling involving a G protein and phospholipase C. That signaling can open transient receptor potential canonical channels, especially TRPC6 and TRPC7. The resulting flow of charged particles into the cell can depolarize it and change intracellular calcium. () The 2026 paper’s significance statement links this TRPC branch to mammalian target of rapamycin signaling, a cellular growth-control pathway. In the new study, removing TRPC6 and TRPC7 largely reduced the melanopsin-associated regeneration in alpha retinal ganglion cells. That is evidence that these channels contribute to the growth response; it does not mean that simply opening TRPC channels would be a safe or sufficient treatment. Calcium signaling can support cell activity, but excessive or poorly controlled calcium can also harm stressed neurons. () The slower branch: adenylyl cyclases and cyclic adenosine monophosphate The second response involves adenylyl cyclases 2, 4, and 7, which can make cyclic adenosine monophosphate—often written as cyclic adenosine monophosphate or cAMP, not to be confused with other cyclic nucleotides. The paper identifies a slower, cyclic-adenosine-monophosphate-linked light response in OPN4-expressing alpha cells and describes a role for protein kinase A in its growth mechanism. () Removing the three adenylyl cyclases largely attenuated regeneration in the OPN4-expressing alpha cells. Supplying cell-permeant cyclic adenosine monophosphate reportedly rescued that knockout effect. It also increased regeneration in some OPN4-expressing non-alpha cells, which suggests that a weak cyclic-adenosine-monophosphate signal may be one barrier to growth in at least some cell types. It does not establish that cyclic adenosine monophosphate alone can replace every effect of melanopsin. () Why cell type matters—and why “resistant” does not mean “regenerative” Retinal ganglion cells are a varied population. Different types can differ in their vulnerability to injury, their survival, their growth capacity, and the brain targets they normally connect to. In mouse optic-nerve-injury experiments, alpha retinal ganglion cells have shown relatively strong survival and growth responses to some treatments, in part associated with stronger growth signaling and expression of factors such as osteopontin and insulin-like growth factor 1. But this advantage does not extend uniformly to every alpha subtype or every injury. () Intrinsically photosensitive retinal ganglion cells are relatively resistant to some acute injuries. A 2016 study found that certain melanopsin-positive cells maintained mammalian target of rapamycin activity after optic nerve injury. Yet the same research also found that native melanopsin-positive cells did not themselves show the robust regeneration seen in some alpha cells after growth-promoting treatments. Survival and regeneration are related, but they are not interchangeable. () Glaucoma adds another complication. It is not a one-time crush: it is generally a chronic disease in which damage unfolds over time. Some studies suggest that specific retinal ganglion cell types, including some alpha OFF-transient cells, may be more vulnerable than others. Melanopsin-positive cells may be relatively preserved in some animal and human samples, but human evidence is limited, and not all melanopsin-cell subtypes respond the same way. The OPN4 approach could therefore act strongly on cells thaSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/a-steroid-injection-during-glaucoma-surgery-was-linked-to-dangerous-low-eye-pressure-what-a-new-randomized-trial-foundTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:A Steroid Injection During Glaucoma Surgery Was Linked to Dangerous Low Eye Pressure — What a New Randomized Trial Found Research checked through November 4, 2026. A small randomized trial published on October 29, 2026, raised a serious safety question: could a long-acting steroid injection given during glaucoma drainage-device surgery suppress healing so much that the eye drains too freely? In the trial, late-onset low eye pressure occurred in 10 of 19 eyes given triamcinolone around the implant, compared with none of 20 control eyes. Seven of the 10 affected eyes needed another operation. That is a striking signal—but it does not show that ordinary steroid eye drops after glaucoma surgery are dangerous, nor that every drainage device or steroid regimen carries the same risk. The study tested one 20-milligram depot injection with one non-valved implant, in a small group of people with difficult-to-control glaucoma. Important details about the pressure threshold, the timing of individual cases, and their recovery are not reported in the publicly available abstract or registry. Trial report on PubMed Trial record on ReBEC What the new randomized trial tested Treatment, injection location, and masking The study included 39 eyes from 39 people with refractory primary open-angle glaucoma. All were undergoing Susanna UF glaucoma drainage-device surgery; the registry says participants had failed at least one prior trabeculectomy. Twenty eyes were assigned to the device alone, and 19 to the device plus triamcinolone. Follow-up lasted six months. The journal describes the study as multicenter and randomized. Trial report on PubMed Trial record on ReBEC The triamcinolone was 20 milligrams: 0.5 milliliters of a 40-milligram-per-milliliter suspension. It was injected into the sub-Tenon’s space around the implant plate, immediately before the conjunctiva—the tissue covering the white of the eye—was closed. This is a depot injection beside the implant, not an injection into the inside of the eye. Trial record on ReBEC The published abstract says that patients and outcome assessors were masked. The registry says a sham injection might have been used to mask the surgeon, but also allows that no sham was performed. So, based on the public records, surgeon masking cannot be confirmed. The registry also does not provide the full surgical recipe: it does not establish whether the tube was tied, fenestrated, or internally stented, or whether mitomycin C was used. Those details matter because they can change how much fluid flows through the device. Trial report on PubMed Trial record on ReBEC There are two further cautions. The registry lists a target of 48 participants, but only 39 were enrolled; recruitment stopped early because of safety concerns. It also records a first enrollment date in December 2020 and a public registration date in July 2025. Late public registration does not prove that results were reported selectively, but it limits confidence that every outcome and analysis was publicly specified before enrollment began. All 39 enrolled participants completed six-month follow-up. Trial record on ReBEC What the trial found For the full table, please open this article on visualfieldtest.com. The injection did not provide an additional pressure-lowering benefit at six months. Average pressure was about 14 mmHg in both groups, and the reduction from baseline was almost identical. A similar group average does not rule out serious low-pressure episodes in individual eyes: averages can hide a wide range of outcomes. Trial report on PubMed The seven operations were performed in seven of the 10 eyes with late-onset hypotony. The public report does not say what procedures were used, when each operation occurred, or whether each eye’s pressure and vision ultimately recovered. Trial record on ReBEC What is—and is not—known about the complications The registry reports these additional events: For the full table, please open this article on visualfieldtest.com. The registry defines a serious-complication group as late hypotony or malignant glaucoma. That composite was 52.6% in the triamcinolone group and 5% in controls. The single control event was malignant glaucoma; it was not a case of late hypotony. The published abstract separately reports late hypotony as 10 of 19 versus zero, and clinically significant hypotony requiring reintervention as seven of 19 versus zero. Trial report on PubMed Trial record on ReBEC The public abstract and registry do not give an exact numerical definition of hypotony or the threshold used to label an event “late-onset.” They also do not give the month each case began or how long it lasted. The registry reports no statistically significant difference in average visual acuity at follow-up, and no event directly related to the intervention led to loss of light perception. But it does not report how many individual patients lost lines of vision, or provide separate counts for choroidal detachment, hypotony-related macular changes, shallow front chamber, or bleb leaks. Those outcomes should be treated as not reported, not as confirmed zero events. Trial record on ReBEC The registry says that de-identified participant-level data may be requested from the investigators, subject to a research proposal and ethics approval. That dataset would be needed to learn the exact case timelines and individual outcomes. Trial record on ReBEC Why might a steroid depot lead to too much drainage? The capsule around an implant helps regulate flow A drainage device carries fluid from inside the eye to tissue around its plate. As healing proceeds, a fibrous capsule forms around that plate. The capsule is not merely scar tissue to eliminate: it also provides much of the resistance that regulates drainage. Too much scarring can restrict flow and raise eye pressure; too little capsule resistance can allow excessive flow and lower pressure too far. American Academy of Ophthalmology overview of drainage devices Evidence supports the general pathway, but not the precise explanation for this trial. A broad review describes how inflammation and fibroblast activity contribute to wound healing and scarring after glaucoma surgery. A separate report described three patients on long-term systemic immune-suppressing treatment who developed persistent hypotony after non-valved implants; their implant capsules were thin and immature. That makes it biologically plausible that strong suppression of healing could reduce capsule resistance. But those cases involved chronic systemic treatment, not a one-time 20-milligram injection of triamcinolone around a Susanna device. The Susanna trial did not measure capsule thickness or fluid flow. Wound-healing review Capsule histology case report The most plausible explanation is therefore an inference: if the depot reduced inflammation and capsule formation around the plate, the outflow pathway may have had less resistance. That could lead to excess drainage, especially once any temporary restriction on tube flow weakens or opens. The trial’s public records do not establish the timing of hypotony relative to tube opening, or even the exact tube-restriction method used. So this mechanism is reasonable, but unproven for these eyes. A depot is not the same as adjustable eye drops A depot injection leaves a suspension near the implant that releases medicine over time. A study of sub-Tenon’s triamcinolone after cataract surgery describes drug delivery lasting several weeks, though the duration can vary. In contrast, eye drops deliver a dose with each use; clinicians can taper or stop them based on the eye’s inflammation and healing. Randomized study of 20-milligram sub-Tenon’s triamcinolone after cataract surgery Crucially, both arms in the Susanna trial received postoperative dexamethasone eye drops—initially six times a day, then gradually reduced over six to eight weeks. The randomized difference was the added depot injection. The trial therefore does not show that routine postoperative steroid drops caused the hypotony signal. It tested a long-acting injection on top of the same drop regimen given to controls. Trial record on ReBEC Steroids can also raise eye pressure in some patients, particularly with prolonged exposure. That is a different effect from the suspected mechanism here: the concern is not that triamcinolone directly lowers pressure inside the eye, but that it might change wound healing and reduce resistance around a drainage pathway. How the findings compare with other glaucoma surgeries For the full table, please open this article on visualfieldtest.com. Why the results may differ Valved versus non-valved devices. The Ahmed valve is designed to restrict flow as pressure becomes low. Susanna UF and Baerveldt implants are non-valved, so they lack that same built-in valve. Non-valved implants are commonly managed with temporary tube ligatures, stents, or other flow-control steps, but the Susanna trial’s public records do not say exactly which were used. In a pooled analysis of three randomized tube-surgery trials, chronic hypotony was uncommon overall—4.1% by five years—but the risk was higher Support the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/could-eye-blood-flow-scans-predict-glaucoma-progression-better-than-regular-oct-new-4-year-resultsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Could Eye Blood-Flow Scans Predict Glaucoma Progression Better Than Regular OCT? New 4-Year Results Short answer: Optical coherence tomography angiography (OCTA) may reveal glaucoma-related change when conventional retinal thickness measurements are no longer changing clearly—especially in some eyes with advanced glaucoma. But the new study does not prove that OCTA is superior to structural optical coherence tomography (OCT). It found an association between faster vessel-density loss and visual-field progression; it did not make a formal comparison of how well the two tests predict progression, and important methodological details are not available in the abstract. A key wording point: OCTA is not a direct blood-flow meter. It detects a signal from moving blood cells and maps vessels that are flowing fast enough to be detected. A falling vessel-density reading may reflect reduced flow signal, capillary loss, image quality, or a combination of these—not necessarily vessels physically disappearing. American Academy of Ophthalmology OCTA assessment What the October 28, 2026 study found The study, “Longitudinal OCT Angiography Versus Structural OCT for Predicting Visual Field Progression in Glaucoma,” was published in the Journal of Glaucoma on October 28, 2026. It followed 333 eyes with open-angle glaucoma, including 110 eyes with normal-tension glaucoma, for an average of 4.1 years. The reported results support OCTA as a potentially useful additional monitoring signal—but do not establish that it should replace OCT or visual-field testing. Journal of Glaucoma article record What can—and cannot—be reconstructed The study’s accessible abstract reports that it was a prospective study. The glaucoma eyes were followed quarterly; 60 age-matched healthy control eyes were examined at the start and again after six months. The researchers tracked: Peripapillary capillary vessel density: the capillary signal around the optic nerve. Macular vessel density: the capillary signal in the central retina, including the parafoveal area. Peripapillary retinal nerve fiber layer thickness: a structural OCT measurement around the optic nerve. Macular ganglion cell–inner plexiform layer thickness: a structural OCT measurement of retinal cells important to vision. Visual-field progression: worsening in the patient’s measured field of vision. The researchers compared change rates with linear mixed-effects models and used multivariable Cox models with cumulatively updated change rates as time-dependent predictors. Visual-field progression was described as being determined with combined event-based and trend-based criteria. Journal of Glaucoma article record There is an important limit to what can be verified: the accessible abstract does not provide the scan device, exact visual-field criteria, glaucoma-stage definitions, full list of model adjustments, or all numerical results. It also does not give confidence intervals for the structural-OCT hazard ratios or the rates of change in the healthy controls. I could not verify those details from a full Methods section or supplement for this review. They should not be guessed. The reported numerical results For the full table, please open this article on visualfieldtest.com. The macular vessel-density loss rates differed by 0.72 percentage points per year between progressors and nonprogressors; the peripapillary rates differed by 0.17 percentage points per year. The hazard ratios mean that, in the model, faster vessel-density loss was associated with a higher rate of visual-field progression. They do not tell a patient’s absolute chance of losing vision, and they do not show that a vessel-density change caused the field loss. The retinal nerve fiber layer and ganglion-cell layer rates were not statistically significant independent predictors in the reported adjusted models. That does not prove that structural OCT is useless, nor does it prove OCTA is better. A significant result for one measure and a nonsignificant result for another is not, by itself, a formal statistical test that one test outperforms the other. The abstract says the Cox models were multivariable, but it does not identify the adjustment variables. Therefore, it is not possible to confirm from the accessible report whether the vessel-density associations remained after accounting for blood pressure, age, glaucoma severity, signal quality, cataract, myopia, or other factors. Nor can the inclusion of 110 normal-tension glaucoma eyes establish a specific OCTA benefit for that subgroup: separate normal-tension results are not provided in the abstract. Journal of Glaucoma article record Why OCTA may add information when structural OCT appears flat Structural OCT can reach a measurement floor Structural OCT measures tissue thickness. In advanced glaucoma, the retinal nerve fiber layer can become so thin that much of the remaining signal comes from non-neural tissue, such as glial tissue and blood vessels. Further nerve-cell damage may then produce little measurable change in the thickness number—a measurement floor. The floor varies by device and measurement method. In one advanced-glaucoma study, average peripapillary nerve fiber layer measurements reached an estimated floor around a visual-field mean deviation of −17.5 decibels, while some macular vessel-density measures remained measurable at more severe field loss. Other studies have found that some macular ganglion-cell tissue remains above its floor in parts of the retina even when the peripapillary nerve fiber layer is near its floor. So the practical point is not that all structural OCT fails in advanced disease: macular ganglion-cell measurements may continue to help, depending on the eye and the region measured. OCT/OCTA floor study Structural OCT floor study Vessel-density measures may retain a signal deeper into disease—but are not floor-proof Some OCTA measurements have shown a longer usable range into severe disease than thickness measurements. In one analysis, parafoveal vessel density had no detectable floor within the study’s observed range, while structural nerve fiber and ganglion-cell measures showed floors at less severe visual-field loss. But a different study found that OCTA measures often had fewer reliable measurement steps across their full range than structural OCT measures, partly because OCTA has its own test–retest variability. The result is a trade-off: OCTA may remain measurable later, but that does not automatically make it easier to detect a small, genuine change. OCTA and OCT measurement-floor comparison OCTA measurement-floor study The scan measures a vascular signal, not the health of a nerve cell directly OCTA can show a change in capillary signal in a retinal region where thickness values are stable. That may be useful because retinal ganglion cells and their nerve fibers depend on blood supply, and capillary signals can change without a measurable change in the thickness of the tissue being scanned. But OCTA does not directly measure oxygen delivery, blood-flow volume, or whether each nerve cell is alive. A reduction in its signal may occur because flow has slowed below the instrument’s detection threshold, because capillary pathways have changed, or because of image artifacts. A “vessel-density loss” should therefore be read as a change in the scan’s flow-related vascular signal—not as a literal count of vanished blood vessels. American Academy of Ophthalmology OCTA assessment Do vascular changes cause nerve damage, or follow it? Both explanations are plausible, and current clinical imaging studies do not settle the question. Hypothesis 1: reduced or unstable blood supply contributes to nerve injury The retina and optic nerve need a steady supply of oxygen and energy. If blood supply becomes inadequate or poorly regulated, nerve cells may be more vulnerable to stress. Blood-pressure changes, low ocular perfusion pressure, and impaired vascular autoregulation have all been investigated in glaucoma. A vascular contribution could be particularly relevant in normal-tension glaucoma, where damage occurs even without a high measured eye pressure. Longitudinal studies showing vessel-density change before later visual-field change fit this hypothesis, but they do not prove it. An earlier scan change may indicate that vascular stress is part of the disease process—or simply that the vascular measure detects damage earlier than a later test. Review of the retinal neurovascular unit in glaucoma American Academy of Ophthalmology Preferred Practice Pattern Hypothesis 2: damaged nerve cells need less blood The opposite direction is also reasonable: if retinal nerve cells are damaged or less active, they may need less energy and therefore less blood supply. Capillary signals could decline because the neural tissue is already deteriorating. Under this explanation, OCTA is an indirect marker of injury rather than a cause of it. Most likely: the relationship is mixed and may run both ways The evidence is consistent with a coupled process: vascular regulation and nerve-cell health may influence one another, while glaucoma and other patient factors affect both. Importantly, a scan showing a vascular Support the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/once-glaucoma-starts-progressing-how-hard-is-it-to-stop-a-new-12-year-study-gives-an-answerTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Once Glaucoma Starts Progressing, How Hard Is It to Stop? A New 12-Year Study Gives an Answer A first confirmed visual-field progression event is a warning—not a guarantee that vision will keep worsening. But a large, long-running study from Bascom Palmer Eye Institute suggests that a meaningful share of eyes do progress again, even while receiving routine care. Published online in JAMA Ophthalmology on October 22, 2026, the study found that recurrence was more likely when vision had been declining quickly before the first event and when average eye pressure remained higher afterward. More pressure reduction was associated with less recurrence, but this was an observational study: it cannot prove that treatment escalation caused the difference. () What the Bascom Palmer study measured Researchers reviewed records from 7,457 eyes belonging to 5,086 people with open-angle glaucoma or suspected glaucoma. The records spanned 1998 to 2025. Across the full group, average follow-up was 12.4 years, with an average of 12.3 visual-field tests per eye. A visual-field test measures how well a person sees in different parts of their field of vision. The first progression analysis included all 7,457 eyes. The recurrence analysis was narrower: 1,951 eyes had an initial “likely progression” event, but only 635 had enough later visual-field tests and eye-pressure records for the researchers to assess recurrence. The recurrence results therefore describe this smaller, well-monitored group—not every eye in the original registry. () How the study defined a progression event The researchers used Guided Progression Analysis, a tool for comparing visual-field test results over time. It compares later tests with the average of the first two reliable tests and looks for worsening at the same test locations beyond the amount expected from normal test-to-test variation. An eye met the study’s definition of “likely progression” when three or more of the same locations worsened on three consecutive examinations. The event was dated to the first of those three examinations. This is a repeatable, computer-based signal—not a guarantee that every flagged change represents irreversible glaucoma damage without any possible test or eye-health influence. () To look for a second event, the researchers reset the comparison: the first progressing visual field and the next examination became the new baseline tests. They then reapplied the same progression rule to the remaining tests. The recurrence analysis required at least four visual-field tests after the first progressing examination. () How often did progression recur? Across the full cohort, 1,951 of 7,457 eyes—26.2%—had an initial likely-progression event. Among the 635 eyes with enough subsequent testing and pressure data, 167—26.3%—had a recurrent event during the follow-up available to the study. () The researchers also used a time-to-event method that accounts for eyes having different lengths of follow-up. Its estimated cumulative recurrence was: For the full table, please open this article on visualfieldtest.com. At the 3-year mark, the 95% confidence interval was 11.6% to 17.1%; at 5 years, it was 22.1% to 29.5%; and at 10 years, it was 35.8% to 52.1%. The number at risk fell from 635 at the start to 30 at 10 years; it was 578 at 2 years, 382 at 4 years, 151 at 6 years, and 45 at 8 years. The 10-year estimate is therefore much less precise than the earlier estimates. () These numbers are not contradictory: 26.3% is the share of the 635 eyes with a recurrence recorded during their available follow-up. The 43.5% figure is the estimated cumulative chance by 10 years, accounting for differences in follow-up time. It does not mean that 43.5% of all 7,457 eyes recurred. The paper also notes that recurrence was recorded more often in the 635-eye analysis than in the broader group of eyes with initial progression—26.3% versus 15.2%—in part because eyes without enough later tests could not register a recurrence. () Which eyes were more likely to progress again? The strongest signal was how quickly the visual field had already been worsening. In the study’s adjusted analysis, each 1-decibel-per-year faster loss in mean deviation—a summary measure of visual-field damage—was associated with a 73% higher hazard of recurrence. “Hazard” describes the relative rate of a new event over time; it is not the same as an individual’s absolute probability of recurrence. () Other adjusted associations included: Higher average eye pressure after the first event: each additional 1 millimeter of mercury was associated with a 9% higher recurrence hazard. Greater pressure reduction: each additional 10% of reduction from the pre-event average was associated with an 11% lower hazard. The pressure level and percentage reduction were analyzed in separate models because they were related; they should not be added together as if they were independent effects. Older age: each additional five years was associated with roughly an 8% to 11% higher hazard, depending on the model. Visual-field damage at the first event: eyes with a less negative mean-deviation score—generally less advanced loss—had a higher measured recurrence hazard. The authors cautioned that progression can be harder to detect in advanced disease because damaged test locations have less remaining range to worsen. () The study’s combined prediction model had moderate, not high, ability to distinguish which eyes would recur. It is a useful risk signal, not a validated calculator for an individual patient. () Fast progressors stood out Among 96 eyes losing more than 1 decibel per year before the first event, 42.7% had recurrent progression, compared with 23.4% of slower-progressing eyes. The difference was about 19 percentage points. () This does not mean that every fast-progressing eye will worsen again, or that every slower-progressing eye is safe. It does mean that the earlier rate of change contains important information: a first progression event in an eye that was already losing field quickly deserves particular attention. What happened to fast-progressing eyes after the first event? The study compared the change in mean-deviation slope for fast-progressing eyes that did and did not have a recorded recurrence: Fast progressors without a recorded recurrence slowed from about −1.71 to −0.39 decibels per year after the first event. Fast progressors with recurrence slowed less, from about −1.70 to −1.31 decibels per year. The groups’ pre-event slopes were nearly identical. Afterward, the nonrecurrence group had a lower average pressure—14.0 versus 16.2 millimeters of mercury—and a pressure reduction greater than 20% was more common among them, 36.4% versus 12.2%. These are striking observations, but they do not establish why the groups’ courses diverged. () Does this show that stronger pressure lowering changed the disease course? It is consistent with that possibility, but it is not proof. Pressure lowering is already supported by randomized trials as a way to reduce glaucoma progression. In the Bascom Palmer study, recurrence was also associated with higher post-event pressure, and eyes with a larger pressure reduction tended to fare better. But the study did not randomly assign people to different pressure targets or treatment plans. () Several other explanations could contribute: Regression to the mean: an eye selected because it had a particularly steep prior decline or a triggering progression event may show a less extreme slope later, even without an effective treatment change. This is especially relevant when comparing a very fast pre-event period with the period afterward. Treatment-selection bias: clinicians may intensify treatment for eyes thought to be at greatest risk. In observational data, treatment and disease severity are intertwined, and the direction of the resulting bias is not predictable. Unknown treatment and adherence: the investigators did not have records of medication changes, laser treatment, surgery, or how consistently treatment was used. A lower recorded pressure could reflect any mix of treatment changes, improved adherence, or ordinary variation. Selection and follow-up: only 635 of the 1,951 eyes with initial progression had the post-event tests and pressure data needed for this analysis. Eyes that remain in care and receive more tests also have more opportunity for another event to be detected. Long-term estimates depend on assumptions about eyes that leave follow-up. () So the study supports a clinically plausible message—pressure reduction may help after progression is detected—but it does not show that a particular escalation caused the slowing seen in one subgroup. What does the pressure after the event tell us? The proportion of eyes with a recorded recurrence rose across the study’s categories of average post-event pressure: For the full table, please open this article on visualfieldtest.com. These are crude recurrence proportions by pressure category, not proof of a safe cutoff or a guarantee that a particular pressure prevents damage. The analysis found a graded association, but some eyes still progressed even when their recorded average was 12 millimeters of mercury oSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/scientists-protected-glaucoma-nerve-cells-without-lowering-eye-pressure-could-mitochondria-become-the-next-treatment-targetTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Scientists Protected Glaucoma Nerve Cells Without Lowering Eye Pressure — Could Mitochondria Become the Next Treatment Target? Short answer: possibly—but the new study is a promising prevention result, not yet proof that mitochondrial treatment can restore vision after glaucoma damage is established. The study at the center of this question was first published in Advanced Science on October 18, 2026. Researchers used adeno-associated virus serotype 2 to increase A-kinase anchoring protein 1, or AKAP1, in the retina. Treated mice retained more retinal ganglion cells, had better electrical responses, and showed stronger tracer labeling along the projection to the brain—even while their eye pressure remained elevated. The results support the idea of pressure-independent neuroprotection. They do not show that treatment lowered pressure, nor do they show that it rescued neurons after damage was already measurable. The October 2026 Advanced Science paper () That distinction matters. A treatment given before pressure injury may prevent cells from becoming dysfunctional or dying. A treatment given after visual function has declined would have to do something more: restore function in living but impaired cells, rebuild lost connections, or both. The study did not test that harder question. What AKAP1 does AKAP1 is a signaling scaffold, a protein that helps hold other signaling proteins in a useful place. It is normally attached to the outer membrane of mitochondria, the cell’s energy-producing structures. AKAP1 is not itself an energy-producing enzyme. Its importance is that it helps organize signals near the mitochondrion, where those signals can influence mitochondrial shape, stress responses, and survival. One important partner is protein kinase A, or PKA. AKAP1 can anchor PKA close to mitochondrial targets, including the fission protein DRP1. PKA-mediated phosphorylation of DRP1 at a particular site—serine 637 in the mouse numbering used in this work—usually makes DRP1 less able to drive mitochondrial fission. The calcium-sensitive enzyme calcineurin can remove that phosphate, which can favor DRP1 activity and mitochondrial division. Earlier laboratory work found that loss of AKAP1 in mouse retina was associated with lower DRP1 phosphorylation, more fragmented mitochondria, abnormal respiratory-chain proteins, and signs of oxidative and cell-death stress. The earlier retinal AKAP1 study () Mitochondria need both fusion and fission. Fusion can help mitochondria share contents and maintain function. Fission helps separate damaged parts, support mitochondrial transport, and allow quality-control processes such as mitophagy. The goal is not simply “more fusion.” It is a healthy balance that changes appropriately with a cell’s needs. AKAP1 is also linked to OPA1, a protein on the inner mitochondrial membrane that helps govern fusion and the structure of the folds called cristae. But the new study did not show that AKAP1 physically binds OPA1. It showed that OPA1 levels changed along with AKAP1 treatment. The direct mechanistic case is stronger for the AKAP1–PKA–DRP1 relationship than for any direct AKAP1–OPA1 interaction. Mitochondria also help manage cellular calcium and supply energy for processes such as nerve signaling and the release of neurotransmitters. It is therefore biologically plausible that mitochondrial stress could affect both calcium-sensitive signaling and synaptic performance. But in the new study, calcium handling was not directly measured, and the investigators did not establish that AKAP1’s synaptic effects were caused by restoring a particular calcium pathway. The authors themselves note that they did not measure PKA catalytic activity, recruitment of PKA to mitochondria, or formation of the AKAP1–PKA complex. () Is AKAP1 reduced in people with glaucoma? Not in the new October 2026 study: that study is based on mouse models and cultured retinal cells, not human donor retina. Its central experiments do not establish how AKAP1 changes in human glaucoma. There is, however, relevant human-tissue evidence in a separate study. In a small postmortem series, AKAP1 staining was lower within retinal ganglion-cell bodies from glaucoma donors. The overall retinal signal was not simply lower: AKAP1 staining was higher in some broader retinal measurements, apparently because AKAP1 was also increased in Müller glial cells. In other words, the answer depends on which cell type and which retinal region are measured. The human evidence is encouraging, but it is small, cross-sectional, and cannot tell whether the AKAP1 change caused degeneration or occurred in response to it. Related study including human donor retina () FACT: A separate small human-tissue study reports lower AKAP1 signal in glaucoma retinal ganglion-cell bodies. STRONG INFERENCE: AKAP1 may be relevant to human disease, but it is not yet established as a consistently reduced, causal driver across glaucoma patients. What the October 2026 study actually did The researchers used two mouse models and a set of cell-culture experiments. The treatment was a viral vector carrying mouse Akap1 under a broad cytomegalovirus promoter. The vector was not restricted to retinal ganglion cells; other retinal cells could also receive it. DBA/2J spontaneous glaucoma DBA/2J mice develop glaucoma as they age. The researchers injected the vector into the vitreous of 5-month-old mice and assessed them at 10 months. Age-matched DBA/2J-Gpnmb-positive mice, which do not develop the same glaucoma phenotype, served as non-glaucomatous controls. Only DBA/2J mice with recorded intraocular pressure between 20 and 35 millimeters of mercury were included in the glaucoma analyses. Across the screening cohort, 64 of 98 10-month-old DBA/2J mice had confirmed pressure elevation. The methods report peak-pressure averages of 21.5 ± 4.5 millimeters of mercury in right eyes and 19.9 ± 3.7 millimeters of mercury in left eyes for the glaucoma-mouse cohort; these are not presented as the treatment-versus-control means for the specific vector comparison. () The authors report that AKAP1-treated DBA/2J mice had: More retinal ganglion cells in both middle and peripheral retinal regions than glaucoma mice given the null vector. More cholera toxin B tracer labeling in the superior colliculus, a brain region receiving retinal input. Higher pattern electroretinogram and pattern visual evoked potential amplitudes. No improvement in pattern visual evoked potential latency. The vector increased retinal AKAP1 and also increased PKA abundance. The paper reports the main outcomes as statistically significant, but the searchable article text does not give exact group means or percentage improvements for the plots. The figure legends supply sample sizes: 20 mice per group for the pressure panel; 9–18 retinas or mice for retinal ganglion-cell counts; 10 mice per group for electrical responses; and three mice for the superior-colliculus tracer analysis. () Microbead-induced ocular hypertension In the second model, beads were placed in the front of the eye to obstruct fluid outflow and raise pressure. The article’s results section describes vector injection in 3-month-old mice, three weeks before the bead injection. The methods section, however, describes 6-week-old mice being injected with vector before bead administration. This age discrepancy is an internal reporting inconsistency. It does not change the key timing point: the vector was given before ocular hypertension was induced. The bead model produced sustained intraocular pressure in the reported range of 20–30 millimeters of mercury for at least eight weeks. Pressure monitoring did not show a statistically significant difference between AKAP1-vector and null-vector groups. Compared with null-vector mice, AKAP1-treated mice retained more retinal ganglion cells, had better pattern electroretinogram and pattern visual evoked potential amplitudes, and had shorter—more normalized—pattern visual evoked potential latency. The figure legend reports 12–14 mice per group for pressure monitoring and electrical responses, and 7–10 retinal wholemounts per group for retinal ganglion-cell counts. () The researchers also tested pressure-stressed retinal ganglion cells in culture. Cells were transduced with the vector before exposure to elevated hydrostatic pressure or paraquat, an oxidative stressor. AKAP1 improved cell viability and oxygen-consumption measures under stress. This is useful mechanistic support, but it is another pre-injury treatment experiment, not a rescue experiment. What the paper does—and does not—quantify The paper reports directions and statistical significance for many plotted outcomes, but the full-text prose and figure legends do not provide exact numerical means, standard deviations, or percentage changes for most of the outcomes listed below. I have not inferred precise bar heights from figures or invented values. For the full table, please open this article on visualfieldtest.com. The full study gives the sample sizes and qualitative results, but not an accessible numeric table of all plotted outcome values. That limits independeSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/could-cataract-surgery-give-you-a-glaucoma-drug-that-lasts-for-years-the-bimatoprost-releasing-lens-explainedTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Could Cataract Surgery Give You a Glaucoma Drug That Lasts for Years? The Bimatoprost-Releasing Lens Explained Potentially—but not for everyone, and not as a cure for glaucoma. SpyGlass Pharma’s investigational Bimatoprost Drug Pad–Intraocular Lens System, or BIM-IOL, combines an artificial cataract lens with two small drug-releasing pads. The lens is designed to release bimatoprost, a pressure-lowering medicine, for about three years. The early results are striking: in a randomized trial, roughly 96% to 98% of evaluable patients who received the drug-releasing lens were not using additional pressure-lowering drops at 12 months. A much smaller first-in-human study found that 20 of 21 participants followed for three years remained drop-free. Those results make the idea worth taking seriously. But “drop-free” is not the same as “glaucoma-free,” and the strongest three-year result comes from a small, uncontrolled study—not the larger randomized trial. This article reviews the evidence available as of October 18, 2026, including the latest American Academy of Ophthalmology meeting presentation. The BIM-IOL remains investigational and not approved by the United States Food and Drug Administration. AAO 2026 results coverage () What Is the SpyGlass Bimatoprost Drug Pad–Intraocular Lens? During cataract surgery, the cloudy natural lens is removed and replaced with an intraocular lens. The SpyGlass system uses a monofocal artificial lens with two bimatoprost-containing pads attached near the junction between the lens’s clear center and its supporting arms. The lens and pads are placed inside the eye’s capsular bag, where the natural lens used to sit. The pads are positioned outside the main visual area and are designed to release bimatoprost slowly. Unlike an implant placed in the eye’s drainage angle, the BIM-IOL is intended to leave that angle available for future glaucoma procedures. Adding the pads requires preparation of the lens but is intended to fit within a routine cataract-surgery workflow. Published three-year pilot study () The system is designed to deliver medication for three years. That is a design goal supported by laboratory release testing and early human pressure measurements—not yet proof that every patient will receive three full years of effective treatment. What Did the AAO 2026 Presentation Report? At the American Academy of Ophthalmology annual meeting in New Orleans, held October 9–12, 2026, investigator Fiaz Zaman presented 12-month results from SpyGlass’s randomized Phase 1/2 trial. The trial enrolled people with a cataract and either mild-to-moderate open-angle glaucoma or ocular hypertension. AAO 2026 presentation coverage () Trial groups and pressure results A total of 104 people were randomized: For the full table, please open this article on visualfieldtest.com. All participants stopped their existing pressure-lowering treatment for a washout period before the baseline measurements. The exact group mean washout pressures were not included in the public AAO report I could verify. Dividing the reported pressure reductions by the rounded percentages gives an approximate baseline of about 25–27 mmHg, depending on group and measurement time. These are calculated estimates, not separately published baseline figures. AAO 2026 results report () The lower-dose group had a numerically larger reduction than the higher-dose group. That does not establish that 39 micrograms is better: these reported averages do not demonstrate a clear dose-response relationship, and the small groups are not a definitive dose comparison. How many patients were off pressure-lowering drops? At 12 months, the presentation reported that: 98% of patients in the 78-microgram group were off additional pressure-lowering medication. 96% of patients in the 39-microgram group were off additional pressure-lowering medication. Control-group participants were not reported as drop-free in the same sense: they were still using their assigned twice-daily timolol. The company has summarized the combined treated groups as approximately 97% off topical pressure-lowering therapy at 12 months. “Medication-free” here means free of additional pressure-lowering eye drops; patients in the BIM-IOL groups used artificial tears as part of the trial and still received ordinary postoperative eye care. AAO 2026 report and SpyGlass Phase 1/2 results () Vision, corneal cells, and adverse events The reported visual outcomes were reassuring: All evaluable eyes in all three groups achieved best-corrected distance vision of 20/32 or better. Vision of 20/20 or better was reported in 74% of the 78-microgram group, 65% of the 39-microgram group, and 63% of the control group. Average vision across groups was about 86 letters, roughly equivalent to 20/20 vision. The presentation also reported corneal endothelial cell density, a measure of the health of the cells lining the inside of the cornea: For the full table, please open this article on visualfieldtest.com. The investigators characterized the overall safety profile and endothelial-cell loss as comparable to routine cataract surgery. However, the numerically larger decline in the smaller 39-microgram group deserves follow-up. These are calculations from reported group averages; the public conference coverage does not provide a full adjusted comparison or enough detail to interpret the differences confidently. AAO 2026 safety and vision results () Any adverse event was reported in 21 people in the 78-microgram group (41%), 10 in the 39-microgram group (43%), and 11 in the control group (37%). The report described no serious adverse events, secondary surgical interventions, or lens explantations through 12 months. The public report does not provide a complete event-by-event breakdown, so the overall percentages should not be read as the proportion who had a problem caused by the drug pads. () How Meaningful Is a 96–98% Drop-Free Result? It is a meaningful early signal. If confirmed in larger and longer studies, avoiding daily pressure-lowering drops could reduce the burden of remembering, handling, and paying for them. That could matter especially for people who struggle with daily dosing. But the headline needs context. It does not mean 98% of patients stopped drops they were taking About one-third of trial participants were taking no pressure-lowering medication at screening. They may have had elevated pressure without current treatment, or they may have been suitable for observation under their clinicians’ care. So the reported drop-free percentage is not the same as saying that 96–98% of people who had been using drops successfully stopped them after surgery. The report does not provide enough detail to calculate that specific number. AAO 2026 study details () The control group also had a large pressure reduction The control group had ordinary cataract surgery, received a standard lens, and used timolol. Its reported pressure reduction—about 35% at 12 months—was close to the reductions in the drug-pad groups. This trial therefore supports the idea that the BIM-IOL can maintain pressure control while avoiding assigned timolol drops; it does not show that the BIM-IOL lowered pressure more than the control treatment. Cataract surgery itself can lower pressure, especially when the starting pressure is high. Estimates differ depending on the patients studied and whether pressure-lowering medications were stopped before measurement. A 2024 review of cataract-surgery trials found a 12-month average reduction of about 3.8 mmHg overall, with a larger average reduction in studies that used a medication washout. Cataract-surgery meta-analysis () “Drop-free” is not the same as “glaucoma controlled for life” The Phase 1/2 trial reported eye pressure, vision, medication use, and safety. It did not establish that the lens prevents future visual-field loss, stops optic-nerve damage, or removes the need for future glaucoma care. The 12-month results are also interim data presented at a medical meeting; the available report is not a full peer-reviewed paper with all trial details. Bottom line: the result is promising evidence of a strong chance of being free from additional pressure-lowering drops at one year in this selected study group. It is not yet proof that most people having cataract surgery can avoid glaucoma treatment indefinitely. Does the Pressure-Lowering Effect Really Last Three Years? The most direct human evidence comes from a small, prospective, nonrandomized first-in-human study in Honduras. The published paper says 24 people consented; company materials have described 23 people assigned to dose groups. Twenty-one were followed through 36 months. The study tested older configurations containing 75, 150, or 300 micrograms of bimatoprost—not the 39- and 78-microgram doses in the later randomized trial. Published three-year pilot study and company 36-month results () At 36 months, the reported average pressure for evaluable participants had fallen from 25.1 ± 2.5 mmHg after washout to 15.9 ± 2.7 mmHg, a reduction of about 37%. Twenty of 21 participants were still free of topical pressure-lowering medication. All 21 had at leSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/do-alcohol-and-smoking-increase-glaucoma-risk-a-new-9-418-person-study-finds-a-stronger-linkTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Do Alcohol and Smoking Increase Glaucoma Risk? A New 9,418-Person Study Finds a Stronger Link A study published on October 10, 2026, reports that alcohol use and cigarette smoking were more common among people with primary open-angle glaucoma in a large African clinic-based sample. The headline figures are striking: former drinkers had about 49% higher odds of glaucoma, and current smokers about 46% higher odds. But the details complicate the headline. This was a cross-sectional, clinic-based study, not a study that followed healthy people to see who later developed glaucoma. Most cases came from glaucoma clinics, while most controls came from cataract or general medical clinics. The researchers measured recent substance use, not lifetime exposure. And when former drinkers were excluded, the association between current drinking and glaucoma was no longer statistically clear. My overall reading: heavy or repeated binge drinking may modestly contribute to glaucoma risk, but the evidence is not conclusive. The case that cigarette smoking causes glaucoma to develop is weaker. Smoking may, however, speed up structural damage in people who already have glaucoma; that possibility has some direct but limited evidence. The new Eyes of Africa study: what it found The Eyes of Africa analysis included 9,418 people aged 40 or older: 5,189 with primary open-angle glaucoma and 4,229 controls. Participants were enrolled from 2017 through 2023 at 16 centers in Nigeria, Ghana, and Malawi. The researchers used structured interviews to ask about alcohol, tobacco, medications, and other substances, then used statistical models to estimate adjusted odds of being a glaucoma case. The Eyes of Africa alcohol-and-smoking study How cases and controls were recruited The sample was assembled mainly through eye-care clinics, rather than by randomly sampling the population: 98.6% of glaucoma cases came from glaucoma clinics; 1.4% came from community outreach. 93.1% of controls came from cataract clinics or general geriatric clinics; 6.9% came from community outreach. The teams invited consecutive eligible patients, which helps avoid cherry-picking within those clinics—but does not make the clinics representative of the wider population. That imbalance matters. It means the study’s odds ratios describe differences in this selected case-control sample; they are not direct estimates of how much an individual’s chance of developing glaucoma changes. Eyes of Africa study methods How glaucoma was diagnosed The study used the International Society of Geographical and Epidemiological Ophthalmology criteria. In everyday terms, a diagnosis required evidence of damage to the optic nerve, usually supported by a characteristic visual-field defect, an open drainage angle on gonioscopy, and no other eye condition that better explained the damage. In some severely damaged eyes where a usable visual-field test was not possible, advanced optic-nerve damage could support the diagnosis. Controls had no clinical evidence of glaucoma and an eye pressure below 22 millimeters of mercury. Eyes of Africa methods The substance-use article itself does not report glaucoma severity or eye pressure by alcohol or smoking category. A companion report on the same cohort supplies useful context: cases averaged 63.9 years of age versus 61.4 for controls; 76.8% of cases had severe glaucoma in at least one eye at recruitment. Average eye pressure at study entry was 19.8 millimeters of mercury in cases, compared with 14.5 in hospital-based controls and 12.8 in community controls. The cases’ average historical maximum pressure was 24.9. These figures describe the overall cohort—not the drinking or smoking subgroups—and many cases were already receiving treatment. Eyes of Africa cohort profile Age and social differences between groups The glaucoma group was older. Among cases, 29.1% were 80 or older, compared with 21.7% of controls. Cases were also more often male, unemployed, and had completed secondary education or more. In the adjusted model, unemployment was associated with higher odds of being a case (1.23), as was secondary education or higher (1.27). These are social characteristics, not proof that unemployment or education causes glaucoma; they may also reflect differences in health, access to eye care, or diagnosis. Eyes of Africa study results The reported alcohol and smoking figures The study’s adjusted odds ratios, compared with never-users unless otherwise specified, were: For the full table, please open this article on visualfieldtest.com. The reported estimates are real, but they need careful interpretation. “Former drinker” meant no alcohol in the 30 days before the interview, not necessarily someone who had permanently quit after years of heavy drinking. “Current drinker” meant at least one drink in that 30-day period. “Former smoker” meant having smoked more than 100 cigarettes over a lifetime but not in the prior 30 days. These brief definitions do not tell us how much a person used to drink or smoke, for how long, or how long ago they stopped. Eyes of Africa exposure definitions and regression results There is also an important detail about the “heavy episodic drinking” result. In the paper, the measure was the largest amount ever consumed in a single day: more than two drinks versus two or fewer. It did not measure how often this happened or the person’s lifetime total. It is therefore not a reliable measure of sustained heavy drinking, and it is not the same as a well-characterized dose-response analysis. What the study did—and did not—show about dose The study did not record lifetime alcohol units or smoking pack-years. Pack-years combine the number of cigarette packs smoked each day with the number of years smoked. Without these cumulative measures, the researchers could not test whether risk rose steadily with long-term exposure. Among current drinkers, reported monthly consumption did not differ significantly between cases and controls. Among current smokers, the number of cigarettes smoked per day also did not differ significantly. Those comparisons were limited by small numbers at higher exposure levels. The study therefore offers no clear dose-and-frequency curve for either substance. Eyes of Africa alcohol and tobacco patterns Two further results deserve attention: In an analysis restricted to current and never-users, current drinking was not associated with higher glaucoma odds: adjusted odds ratio 0.90 (95% confidence interval 0.78–1.04). The alcohol signal in the main analysis was therefore substantially influenced by the former-drinker group. In that restricted analysis, the association with current smoking remained: adjusted odds ratio 1.62 (95% confidence interval 1.16–2.27). This is still an association within a clinic-based sample, not proof of causation. The team adjusted for age, sex, education, employment, country of birth, and other measured substance-use variables. It did not fully account in its main model for factors such as family history of glaucoma, eye pressure, central corneal thickness, myopia, or a detailed set of medical and vascular conditions. A supplementary model adding body mass index reduced the current-alcohol association until it was no longer statistically significant; the authors reported that several other associations changed less. Eyes of Africa adjusted results and limitations Why do former drinkers look worse than current drinkers? At first glance, the former-drinker result—an odds ratio of 1.49, compared with 1.15 for current drinkers—could seem to suggest that quitting alcohol increases glaucoma risk. That is not a sensible causal interpretation. Several other explanations are more likely. Illness-related quitting and reverse causation People may reduce or stop drinking after a diagnosis, after developing another illness, or when treatment or family circumstances change. If some glaucoma cases had already been diagnosed before the interview, their diagnosis could have influenced their drinking. Because glaucoma often develops unnoticed for years, it is difficult to know whether alcohol use preceded the disease, changed because of it, or both. The Eyes of Africa study does not report when each person stopped drinking relative to glaucoma onset or diagnosis. Its cross-sectional design cannot sort out that sequence. The researchers themselves noted that people may have reduced drinking after diagnosis or health advice. Eyes of Africa discussion The “former drinker” category combines very different people A person who stopped drinking last week and a person who stopped decades ago are both “former drinkers” in this analysis. So are people who drank only occasionally and happened not to drink in the last 30 days. The category does not distinguish illness-related quitting from social, religious, financial, or other reasons for not drinking. This broad grouping can make the former-drinker association difficult to interpret. It also leaves room for sick-quitter bias: people may quit because they are unwell, and their illness—not their quitting—may be associated with glaucoma or with clinic attendance. Age, health, and survival could also contribute Cases were older than Support the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/a-new-glaucoma-procedure-uses-donor-tissue-to-keep-the-eye-s-drainage-canal-open-first-human-results-are-inTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:A New Glaucoma Procedure Uses Donor Tissue to Keep the Eye’s Drainage Canal Open — First Human Results Are In Short answer: The first results are encouraging, but they do not yet show that donor tissue makes canaloplasty more durable. The reported 52-eye study has no published full paper, no control group, and only six months of follow-up. Because the procedure was combined with cataract surgery, some—and possibly a substantial part—of the pressure drop may have come from cataract removal rather than the allograft. The idea is plausible: open Schlemm’s canal, then support it with donor tissue. But the key claim—that this support prevents clinically important canal recoil and improves lasting pressure control—still needs a randomized comparison. Evidence reviewed through October 16, 2026. What the first 52-eye results show On October 8, 2026, Iantrek announced preliminary six-month results from a first-in-human, single-center observational study of bio-reinforced canaloplasty combined with cataract surgery. The company reported outcomes for 52 treated eyes. The full study report was not published with the announcement; the data were described as “on file” and subject to further analysis. (Iantrek’s October 8 announcement, Ophthalmology Management’s report) For the full table, please open this article on visualfieldtest.com. The 14.1 figure is calculated, not separately published: 22.4 × (1 − 0.372) = 14.07. Because the baseline and percentage are rounded, the exact study mean might differ slightly. The medication calculation is also approximate: a 49.1% reduction from 1.2 medications implies a reduction of about 0.59, leaving an average of about 0.61. These are the figures in the company announcement, not independently audited results. “No serious adverse events” does not mean there were no minor events, and a group of 52 eyes followed for six months cannot rule out uncommon complications or late problems. Important study details are not yet public The announcement does not provide enough information to establish several facts requested for a proper clinical assessment: Glaucoma severity and subtype: Not reported for the 52-eye cohort. Patient age: Not reported. Previous selective laser trabeculoplasty or minimally invasive glaucoma surgery: Not reported. Detailed inclusion criteria: Not reported. Medication washout before baseline pressure measurement: Not reported. This matters: a pressure measured after stopping drops is not directly comparable with one measured while patients are taking them. Cataract surgery: The study is described as bio-reinforced canaloplasty performed with cataract surgery. That implies the reported 52 eyes had combined surgery, but the press release does not provide a patient-by-patient study table. Exact surgical steps: The type of dilation, how much of the canal was treated, and the precise graft-placement steps are not reported. Allograft length and exact placement extent: Not reported for AlloSpan. Postoperative eye-drop regimen: Not reported. A separate, ongoing study called BOOST is registered as an observational study of bio-reinforced canaloplasty. Its registry describes placing minimally manipulated, homologous-use scleral allograft tissue in the wall region of Schlemm’s canal after canaloplasty. It targets 300 participants and plans two years of follow-up; it is not a randomized comparison of graft versus no graft. BOOST’s eligibility rules should not be assumed to describe the earlier 52-eye study. (BOOST study record) What “bio-reinforced canaloplasty” means The eye continuously produces clear fluid called aqueous humor. It normally drains through the trabecular meshwork, into Schlemm’s canal, and then through collector channels toward the veins around the eye. In open-angle glaucoma, pressure can rise when this drainage system does not carry fluid away efficiently. Conventional canaloplasty In conventional canaloplasty, a surgeon uses an instrument to enter and dilate Schlemm’s canal, commonly by delivering a viscoelastic fluid. Some versions also place a tensioning suture around the canal; other, newer ab-interno procedures do not. The goal is to stretch the canal and improve flow through the eye’s existing drainage route. The proposed AlloSpan approach Bio-reinforced canaloplasty adds another step: after dilating the canal, the surgeon places homologous donor scleral tissue in the canal-wall region to provide structural support. Public descriptions also characterize the platform as nitinol-guided and trabecular-meshwork-sparing, but the detailed steps used in the 52-eye study have not been published. (BOOST study record, Iantrek’s AlloSpan introduction) The concept is therefore: Conventional approach: Dilate the canal; hope the improved opening and flow persist. Bio-reinforced approach: Dilate the canal, then add a biological scaffold intended to support its structure. The word “reinforced” describes the intended mechanical role. It does not yet establish that the canal stays wider, that collector-channel flow improves, or that pressure control lasts longer. Does Schlemm’s canal actually collapse or recoil after canaloplasty? Canal narrowing is a real feature of eye anatomy. But current evidence does not establish that post-surgical recoil is a major cause of conventional canaloplasty losing effectiveness. What imaging and tissue studies show Anterior-segment optical coherence tomography studies have found that Schlemm’s canal can be larger after canaloplasty. One study documented increased canal dimensions during the first few months after surgery; another examined canal and trabecular-meshwork changes one year after combined cataract surgery and canaloplasty. Those studies support the idea that surgery changes the canal’s anatomy. They do not show that later pressure rises are caused by canal recoil, or that a graft prevents such rises. (Three-month imaging study, one-year phacocanaloplasty imaging study) Laboratory and histological work also shows that the trabecular meshwork can bow toward—and narrow—the canal as pressure changes. But Schlemm’s canal is not simply an empty pipe. Its walls, internal supports, collector-channel openings, and surrounding tissues all respond to pressure. (Histopathological review of trabecular surgery, study of Schlemm’s canal and collector-channel anatomy) Conventional canaloplasty can last for years without an allograft Longer-term clinical results show that conventional canaloplasty can retain meaningful effects, although the evidence is mostly nonrandomized and outcomes vary. In a multicenter three-year study, the overall mean pressure was 15.2, while eyes having combined cataract surgery and canaloplasty averaged 13.6. In a separate ten-year observational study, mean pressure at ten years was 15.9 after canaloplasty alone and 14.2 after combined cataract surgery and canaloplasty. Medication use rose over time in some groups, suggesting that pressure lowering and medication reduction are not the same thing. (Three-year canaloplasty results, ten-year canaloplasty results) These studies do not prove that canal anatomy never changes after surgery. They do show that a donor scaffold is not already known to be necessary for long-term canaloplasty benefit. A key missing link is evidence that patients whose canal later narrows are the same patients whose pressure control fails. A larger canal may not solve all drainage problems Even with a wider canal, fluid must still pass through the collector channels and other downstream tissues. Research suggests a substantial share of resistance can lie beyond Schlemm’s canal, in the collector-channel and venous pathways. So keeping the canal open could help, but it cannot necessarily fix blocked or poorly functioning downstream drainage. (Review of Schlemm’s canal procedures and outflow resistance) How much of the pressure drop could cataract surgery explain? This is the study’s biggest interpretive problem. AlloSpan was not tested against cataract surgery alone or against ordinary canaloplasty. Cataract removal can lower pressure on its own, especially when the pressure before surgery is high. In the randomized HORIZON trial, patients with open-angle glaucoma had a medication-washout baseline mean pressure of about 24.5. At 24 months, the cataract-surgery-only group had an average pressure decrease of 5.3, about 22% of baseline. In an Ocular Hypertension Treatment Study analysis, cataract surgery was associated with a pressure decrease from a higher baseline, but the effect differed according to baseline pressure and medication use. (HORIZON trial report, Ocular Hypertension Treatment Study cataract analysis, analysis of cataract surgery in treated patients) The AlloSpan announcement implies an overall decrease of about 8.3—from 22.4 to about 14.1. As a rough comparison: If the 22.4 baseline was measured after medication washout, cataract-only results in a similar pressure range suggest cataract surgery might explain around 5 millimeters of mercury, or about 22 percentage points of the reported reduction. If baseline was measured while patients were using their usual drops, the cataract-only contribution might be closerSupport the show